ImmunoGen, Inc., a biotechnology company, develops targeted anticancer therapeutics. The company develops its products using its antibody-drug conjugate (ADC) technology. The company’s product candidates include Mirvetuximab soravtansine, an ADC targeting folate-receptor alpha for the treatment of platinum-resistant ovarian cancer; IMGN529 and coltuximab ravtansine that are in Phase II clinical trials for the treatment of non-Hodgkin lymphoma; IMGN779 that is in Phase I clinical trials for the treatment of acute myeloid leukemia (AML); and IMGN632, a preclinical CD123-targeting ADC for the treatment of AML. ImmunoGen, Inc. has collaborations with Amgen Inc.; Bayer HealthCare; Biotest AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; Roche; Sanofi; Merck; and Takeda, as well as research agreement with CytomX Therapeutics, Inc. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.

Read More

IMGN Conference Calls / Webcasts:

Date Time (Eastern) Title
  2/17/17 8:00 am ImmunoGen Inc Earnings (Q2 2017)
  10/28/16 8:00 am ImmunoGen Inc Earnings (Q1 2017)
  8/04/16 8:00 am ImmunoGen Inc Earnings (Q4 2016)
  10/27/15 8:00 am ImmunoGen Inc Earnings (Q1 2016)
  7/31/15 8:00 am ImmunoGen Inc Earnings (Q4 2015)
  1/30/15 8:00 am ImmunoGen Inc Earnings (Q2 2015)
Appstore
StockTwits